ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan
Alumis Inc. and Kaken Pharmaceutical Co., Ltd. have entered into a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001 for dermatology indications in Japan.